Alterations of Myocardial Ketone Metabolism in Heart Failure with Preserved Ejection Fraction (HFpEF)
Veränderungen des myokardialen Ketonstoffwechsels bei Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF)
ESC Heart Failure · 01.08.2025 · 12 (4) · 3179-3182
DOI: 10.1002/ehf2.15319 ↗Auf einen Blick
In einem Mausmodell der HFpEF war die Glukoseoxidation vermindert und die Fettsäureoxidation erhöht. Eine erhöhte Ketonzufuhr steigerte die myokardiale Ketonoxidation, ohne die Herzfunktion zu verbessern.
Fragestellung
Untersucht wurden die Effekte einer erhöhten Ketonzufuhr auf kardiale Energetik und Funktion in einem HFpEF-Mausmodell.
Methode
HFpEF wurde bei 13 Monate alten weiblichen C57BL/6N-Mäusen über 6 Wochen mit 60 % High-Fat-Diet und L-NAME induziert. Verglichen wurden Ketonester-Supplementierung oder Empagliflozin mit HFpEF ohne diese Behandlung.
Ergebnisse
In HFpEF-Herzen war die Glukoseoxidation signifikant vermindert, die Fettsäureoxidation erhöht. β-Hydroxybutyrat steigerte die Ketonoxidation in Kontrollherzen und schwächer in HFpEF-Herzen; unter Ketonester oder SGLT2i normalisierte sie sich.
Schlussfolgerung der Autor:innen
Bei HFpEF schaltet das Herz von Glukoseoxidation auf Fettsäureoxidation um, die Ketonoxidation ist beeinträchtigt. Eine erhöhte Ketonzufuhr steigerte die myokardiale Ketonoxidation, war aber nicht mit funktionellen Verbesserungen verbunden.
Kernaussagen
- HFpEF-Herzen: weniger Glukoseoxidation, mehr Fettsäureoxidation
- Ketonoxidation in HFpEF-Herzen beeinträchtigt
- Keine Verbesserung der Herzfunktion durch Ketonester oder SGLT2i
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 26.05.2025. Verfasst von Qiuyu Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Ketones, Myocardium. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
Cardiac energy metabolism is disrupted in heart failure with preserved ejection fraction (HFpEF), as characterized by a switch from glucose oxidation towards fatty acid oxidation. However, although oxidation of ketones is an important source of ATP it remains unclear how the heart oxidizes ketones in HFpEF. It is also unclear whether elevating ketone supply to the heart can improve cardiac energetics and/or provide functional benefit for the hearts in HFpEF.
Aims
The present study investigated the effects of increasing ketone supply to the heart via ketone supplementation or SGLT2 inhibitor treatment in a mouse model of HFpEF.
Methods
HFpEF was induced in 13-month-old C57BL/6N female mice with 60% high-fat diet and L-NAME (0.5 g/L/day in the drinking water) for 6 weeks. In parallel, two other groups of mice were maintained on the HFpEF protocol while also receiving either a ketone ester supplement (1–3 butanediol 1 g/kg/day) or SGLT2 inhibitor (empagliflozin 10 mg/kg/day) for 6 weeks. Control mice were fed with regular low-fat diet and regular drinking water. Hearts of the mice were excised and perfused in the isolated working mode aerobically with 5-mM glucose, 0.8-mM palmitate, 100-μU/mL insulin, with either low (0.6 mM) or high (1 mM) levels of β-hydroxybutyrate. Metabolic rates of the hearts were measured with radiolabelled [U-14C] glucose, [9,10-3H] palmitate and [3-14C] β-hydroxybutyrate.
Results
In HFpEF mouse hearts, glucose oxidation was significantly decreased with a parallel increase in fatty acid oxidation. Increasing β-hydroxybutyrate levels from 0.6 to 1 mM in the perfusate resulted in a rise in ketone oxidation rates in control hearts (from 861 ± 63 to 1377 ± 94 nmol g dry wt−1 min−1), which was muted in HFpEF hearts (from 737 ± 68 to 897 ± 134 nmol g dry wt−1 min−1). Following ketone ester supplement or SGLT2 inhibitor treatment, HFpEF mice presented with restored ketone oxidation rates (from 674 ± 36 to 1181 ± 115 nmol g dry wt−1 min−1 with ketone ester supplement and from 797 ± 121 to 1240 ± 120 nmol g dry wt−1 min−1 with SGLT2i). Yet, this was not associated with improvement in cardiac function.
Conclusions
In HFpEF mice, the heart switches from glucose oxidation to fatty acid oxidation, with ketone oxidation being impaired. Increasing ketone supply to the heart via ketone ester supplementation or SGLT2 inhibitor treatment increases myocardial ketone oxidation rates but was not associated with functional improvements. Unlike HFrEF, ketone supplementation strategies may be less effective in HFpEF due to an impairment of myocardial ketone oxidation in HFpEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
Zitieren
APA
Sun, Q., Wagg, C. S., Wong, N., Wei, K., Ketema, E. B., Zhang, L., Fang, L., Seubert, J. M., & Lopaschuk, G. D. (2025). Alterations of Myocardial Ketone Metabolism in Heart Failure with Preserved Ejection Fraction (HFpEF). ESC Heart Failure, 12(4), 3179-3182. https://doi.org/10.1002/ehf2.15319
Vancouver
Sun Q, Wagg CS, Wong N, Wei K, Ketema EB, Zhang L, et al. Alterations of Myocardial Ketone Metabolism in Heart Failure with Preserved Ejection Fraction (HFpEF). ESC Heart Failure. 2025;12(4):3179-3182. doi:10.1002/ehf2.15319
BibTeX
@article{Sun2025,
author = {Sun, Qiuyu and Wagg, Cory S and Wong, Nathan and Wei, Kaleigh and Ketema, Ezra B and Zhang, Liyan and Fang, Liye and Seubert, John M and Lopaschuk, Gary D},
title = {Alterations of Myocardial Ketone Metabolism in Heart Failure with Preserved Ejection Fraction (HFpEF)},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {4},
pages = {3179--3182},
doi = {10.1002/ehf2.15319}
}
EUVIMED